MYD88 is frequently mutated in the C5/MCD DLBCL subtypes, with about 50% of the patients harboring the MYD88 L265P mutation.58, 81, 144 MYD88 forms a multiprotein supercomplex in CD79B/MYD88‐mutant cells along with TLR9 and the BCR on endolysosomes (Figure 4).145 This “My‐T‐BCR” supercomplex co‐localizes with mTOR, driving pro‐survival NF‐κB and mTOR signaling. This evidence concerns the gene BCR and diffuse large B-cell lymphoma.